Edding Genor Group Holdings Limited · HKEX:6998

Edding Genor — H1 2022 Earnings Presentation

29 slides from Edding Genor's earnings presentation, August 2022

Slide 2: Disclaimer
Disclaimer By receiving this document or attending the meetings at which this document is presented, you agree to be bound by the following restrictions: This document is provided to you solely for your exclusive use and information and is not for public dissemination. The information contained in t
Slide 3: Agenda
Agenda Business Review 1 2 Pipeline Introduction Upcoming Milestones 3 4 Financial Overview Company Confidential, Copyright© Genor Biopharma Co., Ltd. 2
Slide 4: Business Review
O4 — Business Review GENZ:R ARERItHS :6998.HK
Slide 5: Business Highlights – 1H2022
Business Highlights – 1H2022  Established global innovative platform for IO Bs/MsAb FIC/BIC drug research and discovery  Operation efficiency – Focus, Operation Discovery /  Initiated 5 FIC/BIC bi/multi-specific Restructure, Optimization Efficiency Early Research antibodies projects  Focus on pr
Slide 6: Focus & Acceleration——Achieved several goals of 2022 in advance
Focus & Acceleration——Achieved several goals of 2022 in advance Maintain steady operation & development in next 3 years with current cash flow 2022 2023 2024 2025 GB226 NDA Approval Commercialization with collaboration in China GB242 NDA Approval √ Acceleration cash generation Late-stage Pipeline GB
Slide 7: End-to-end Integrated Platform
End-to-end Integrated Platform Discovery  IO bi/multi-specific antibody  FIC/BIC potential drug design platform  Immune check point inhibitor  T-Cell Engager for solid tumors  Cytokines drug conjugates Business Development  A proven track record of collaborating with biopharmaceutical and biot
Slide 8: Pipeline Introduction
Te 02 — a ») Pipeline Introduction
Slide 9: A Robust Pipeline- Development Stage Assets Focusing on Global Opportunities
A Robust Pipeline- Development Stage Assets Focusing on Global Opportunities Target/MoA Commercial Pre – NDA Product Indication Classification Discovery IND Phase 1 Phase 2 Pivotal (reference drug) Rights Clinical Review CDK4/6+AI (combo w/ letrozole) 1L HR+/HER2- BC GB491 CDK4/6+SERD (combo w/ fulv
Slide 10: GB491 (Lerociclib) – Potential Best-in-Class CDK4/6 Inhibitor
GB491 (Lerociclib) – Potential Best-in-Class CDK4/6 Inhibitor Excellent Efficacy Profile & Better Tolerability • Lerociclib is a potent, selective, CDK4/6 inhibitor with superior tolerability by improving its targeting and pharmacokinetic properties • GB491 can be administrated continuously as good
Slide 11: GB491 (Lerociclib) – Potential best safety profile across the CDK4/6 drug class
GB491 (Lerociclib) – Potential best safety profile across the CDK4/6 drug class • GB491 can be administrated continuously as it has less blood adverse reaction. • GB491 has less gastrointestinal adverse reactions in all grades and has no gastrointestinal adverse reactions in grade 3 or above. Potent
Slide 12: GB491 (Lerociclib) – Expects to submit NDA in China in H2 2023
GB491 (Lerociclib) – Expects to submit NDA in China in H2 2023 Commercialization by business cooperation in APAC countries / regions NDA NDA FPD Submission Approval 2L: (GB491 Ph3 IND 2021.10 2023.H2 2024.H2 2025 Deal Signed + Fulvestrant) Approval 2020.06 2021.05 2021.07 NDA NDA - 2036 FPD Submissi
Slide 13: GB261 – A Highly Differentiated CD20/CD3 BsAb for B-cell Lymphoma
GB261 – A Highly Differentiated CD20/CD3 BsAb for B-cell Lymphoma CN IND approval in May 2022 Phase 1 clinical trial kicked off in China in August 2022 The first T-cell engager with super low CD3 binding affinity and maintaining Fc effector functions (ADCC and CDC) , rendering better safety and mult
Slide 14: GB261 Significantly Inhibits Rituximab-resistant Tumor Growth (in vivo)
GB261 Significantly Inhibits Rituximab-resistant Tumor Growth (in vivo) GB261 induces more Rituxan-resistant Raji cell killing in PMBC-engrafted B-NDG mice than REGN1979 analog. Inoculation BLI and grouping Study endpoint Antibody, IV (1 mg/kg) Antibody, IV (1 mg/kg) HLA-matched hPBMC, IV Vehicle D-
Slide 15: GB261 Induces T cell Activation with Less Cytokine Releases
GB261 Induces T cell Activation with Less Cytokine Releases GB261 stimulates less cytokine release compared to that of REGN1979 analog. T cell activation E/T 1:1 ABS (GB261) REGN1979 Control Target cells: Rituxan resistant Raji cells Effector cells: human PBMC EC50 EC50 EC50 EC50 GB261 – ~2.112e-010
Slide 16: GB261 - The preliminary clinical POC achieved for GB261
GB261 - The preliminary clinical POC achieved for GB261 GB261 Clinical Data Conforms to MOA and Pre-clinical Discovery Preliminarily showed higher starting dose Clinical and Regulatory Progress in 1H2022: Mosunetuzumab Odronextamab Glofitamab Drug Candidate GB261  Australia: (RG7828) (REGN1979) (RG
Slide 17: GB263T – the First EGFR/cMET/cMET Tri-specific for NSCLC
GB263T – the First EGFR/cMET/cMET Tri-specific for NSCLC Global rights, global innovation, blockbuster potential In comparison with JNJ-61186372，GB263T is differentiated in design GB263T JNJ-61186372 (Amivantamab) Multiple MOAs  Inhibit EGFR/c-MET relevant signaling EGFR EGFR  Mediate receptor end
Slide 18: GB263T – Trials in AUS and China
GB263T – Trials in AUS and China CN IND Acception 2020.12 2021.12 2022.03 2022.05 2022.06 2022.07 CMC Kick-off FIH AUS Clinical trial AUS EC Approval FPD in AUS CN IND Approval EC approval Submission Cross-Department Cooperation  Cooperated with world famous PI to design clinical trial  Finalized
Slide 19: GB492 – A Potentially First-in-class STING Agonist in China
GB492 – A Potentially First-in-class STING Agonist in China Complete 400μg mono clinical trial, start combo escalation with PD-1 STING agonist, as an immune stimulatory therapy, may further Mechanism of Action increase the response of immune checkpoint inhibitors for patients Merck’s trial demonstra
Slide 20: GB492 – Advancing Clinical Development
GB492 – Advancing Clinical Development Complete Clinical Readout mono 400μg in USA 2020.06 2021.05 2021.09 2022.01 2H 2022 CDE approval IND Deal Signed Mono FPD for Combo Approval Escalation Progress Achievements:  IND Approval for an innovative FIH trial Design combining 2 dose escalation in one s
Slide 21: FIC Drug Design Strategy and Integrated Drug Development Platform
FIC Drug Design Strategy and Integrated Drug Development Platform FIC Drug Design Strategy Focusing on tumor immunology • BsAb/TsAb • TCEs • Cytokines conjugates FIC Drug Design Platform Company Confidential, Copyright© Genor Biopharma Co., Ltd. 20
Slide 22: New Discovery-stage Pipeline: Focusing on IO FIC Antibodies
New Discovery-stage Pipeline : Focusing on IO FIC Antibodies While Exploring Cutting-edge Technology, one IND per year Discovery-stage pipeline pipeline Indications Lead discovery GBD201 NSCLC, ESCC,other solid tumors FIC  Comprehensive assessment before entering into next stage. GBD202 NSCLC, GC,
Slide 23: Upcoming Events
Upcoming Events
Slide 24: Upcoming Milestones
Upcoming Milestones Key Events Timing Expected milestones achieved in advance GB242 (TNF-α) – Commercial Approval Feb 2022 GB261 (CD20/CD3) – IND Approval in China May 2022 GB261 (CD20/CD3) – Initial POC readout July 2022 GB263T (EGFR/cMet/cMet) – EC approval March 2022 GB263T (EGFR/cMet/cMet) – FPD
Slide 25: Financial Overview
* —— Financial Overview BIOPHARMA
Slide 26: Financial Overview – Income Statement
Financial Overview – Income Statement Six Months Ended 30 June RMB' mn 2022 2021 Revenue 3.0 - Revenue Cost of revenue 0.8 -  Revenue was generated by providing research and manufacturing services to customers under fee-for-service Gross Profit 2.2 - contracts. Selling expenses (63.0) (27.1) Expens
Slide 27: Financial Overview – Balance Sheet
Financial Overview – Balance Sheet RMB' mn Jun-22 Dec-21 Cash and cash equivalents 1,858.2 2,200.6 Restricted bank deposits - 2.0 Inventories 46.5 49.7 Contract cost 1.3 1.8 Cash Balance Other receivables, deposits and prepayments 91.0 132.5  As at 30 June, 2022, our total Total Current Assets 1,99
Slide 28: Q&A
Q&A

Edding Genor Group Holdings — H1 2022 Earnings Presentation on 6ix

Edding Genor — H1 2022 Earnings Presentation

Slide 1: 1H22 Interim Results Presentation

Slide 2: Disclaimer

Slide 3: Agenda

Slide 4: Business Review

Slide 5: Business Highlights – 1H2022

Slide 6: Focus & Acceleration——Achieved several goals of 2022 in advance

Slide 7: End-to-end Integrated Platform

Slide 8: Pipeline Introduction

Slide 9: A Robust Pipeline- Development Stage Assets Focusing on Global Opportunities

Slide 10: GB491 (Lerociclib) – Potential Best-in-Class CDK4/6 Inhibitor

Slide 11: GB491 (Lerociclib) – Potential best safety profile across the CDK4/6 drug class

Slide 12: GB491 (Lerociclib) – Expects to submit NDA in China in H2 2023

Slide 13: GB261 – A Highly Differentiated CD20/CD3 BsAb for B-cell Lymphoma

Slide 14: GB261 Significantly Inhibits Rituximab-resistant Tumor Growth (in vivo)

Slide 15: GB261 Induces T cell Activation with Less Cytokine Releases

Slide 16: GB261 - The preliminary clinical POC achieved for GB261

Slide 17: GB263T – the First EGFR/cMET/cMET Tri-specific for NSCLC

Slide 18: GB263T – Trials in AUS and China

Slide 19: GB492 – A Potentially First-in-class STING Agonist in China

Slide 20: GB492 – Advancing Clinical Development

Slide 21: FIC Drug Design Strategy and Integrated Drug Development Platform

Slide 22: New Discovery-stage Pipeline: Focusing on IO FIC Antibodies

Slide 23: Upcoming Events

Slide 24: Upcoming Milestones

Slide 25: Financial Overview

Slide 26: Financial Overview – Income Statement

Slide 27: Financial Overview – Balance Sheet

Slide 28: Q&A

Slide 29: 1H22 Interim Results Presentation